Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Ways To Enhance Your Budgeting Strategy
This article presents Ways To Enhance Your Budgeting Strategy with incremental tweaks, monitoring, and alignment to goals.
21,926 articles
Gray Divorce: Roth Often Outperforms 401(K) in Asset Splits
As gray divorce cases rise, financial planners warn a simple 50/50 split of retirement accounts often undercuts long-...
Warren Buffett Drops Bombshell on Berkshire’s AI Push
Warren Buffett publicly stated he initiated Berkshire Hathaway’s larger stake in Alphabet, signaling a top-down push ...
Micron Shareholders Received Amazing News at Conference
At a key investor conference, Micron revealed strategic moves and market signals that could alter its trajectory. Her...
Lessons From Investing’s ‘Moneyball’ Moment Reframe Strategy
As markets enter 2026, a century of stock market data underpins a new wave of strategy. This piece distills three les...
Bitcoin Pioneer Jack Dorsey Leads Block Through AI Era Reset
Block announces a sweeping AI-driven overhaul, cutting staff by more than 4,000 and reorganizing around a leaner oper...
Retirees Using 3.56% Yield ETF Rally on Food Inflation
A growing cohort of retirees is turning to a 3.56% yield strategy as grocery bills rise. The Invesco DBA ETF provides...
Oracle Under Pressure From Debt and Massive Layoffs
Oracle confronts a heavy debt burden and sweeping layoffs as it presses ahead with a three-step transformation, raisi...
IBM Falls as Fallen Anthropic Puts Them in Crosshairs
IBM stock slides as Anthropic's AI code tool threatens IBM's COBOL modernization business, forcing investors to repri...
Lilly Falls on Oral Obesity Pill as FDA Decision Looms
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Core Question Freshworks Investors: Buyback Versus AI Risk
Freshworks unveils a $400 million share repurchase as it shifts to AI-based pricing, prompting investor debate over w...
Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status